T2	control 414 423	tamoxifen
T3	eligibility 456 505	postmenopausal women with localized breast cancer
T4	intervention-participants 788 791	335
T5	control-participants 812 815	347
T7	outcome 1147 1162	ES total scores
T8	outcome 1283 1291	diarrhea
T9	iv-bin-percent 1305 1309	3.1%
T10	cv-bin-percent 1324 1328	1.3%
T11	outcome 1331 1346	vaginal dryness
T12	iv-bin-percent 1348 1353	18.5%
T13	cv-bin-percent 1358 1362	9.1%
T14	outcome 1365 1382	diminished libido
T15	iv-bin-percent 1384 1389	34.0%
T16	cv-bin-percent 1394 1399	26.1%
T17	outcome 1406 1417	dyspareunia
T18	iv-bin-percent 1419 1424	17.3%
T19	cv-bin-percent 1429 1433	8.1%
T20	outcome 1508 1517	Dizziness
T21	iv-bin-percent 1519 1523	3.1%
T22	cv-bin-percent 1528 1532	5.4%
T23	outcome 1538 1555	vaginal discharge
T24	iv-bin-percent 1557 1561	1.2%
T25	cv-bin-percent 1566 1570	5.2%
T26	intervention 53 99	"Arimidex", tamoxifen, alone or in combination
T1	outcome-Measure 966 999	Trial Outcome Index of the FACT-B
